Georgina Yan

Georgina Yan

Auto-generated profile, based on publicly available information

Georgina Yan

Southampton Children’s Hospital, Southampton, England, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2022 in Archives of Disease in Childhood - Fetal and Neonatal Edition
Verified
Journal Article
Open access
PDF file
ASAnnalie Shears
Annalie Shears
GYGeorgina Yan
Georgina Yan
HMHarriet Mortimer
Harriet Mortimer
ECElizabeth Cross
Elizabeth Cross
SSShari Sapuan
Shari Sapuan
KFKaty J Fidler
Katy J Fidler
Objective This systematic review evaluates vestibular and balance dysfunction in children with congenital cytomegalovirus (cCMV), makes recommendations for clinical practice and informs future research priorities. Design MEDLINE, Embase, EMCARE, BMJ Best Practice, Cochrane Library, DynaMed Plus and UpToDate were searched from inception to 20 March 2021 and graded according to Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) criteria. Patients Children with cCMV diagnosed within 3 weeks of life from either blood, saliva and/or urine (using either PCR or culture). Intervention Studies of vestibular function and/or balance assessments. Main outcome measures Vestibular function and balance. Results 1371 studies were identified, and subsequently 16 observational studies were eligible for analysis, leading to an overall cohort of 600 children with cCMV. All studies were of low/moderate quality. In 12/16 studies, vestibular function tests were performed. 10/12 reported vestibular dysfunction in ≥40% of children with cCMV. Three studies compared outcomes for children with symptomatic or asymptomatic cCMV at birth; vestibular dysfunction was more frequently reported in children with symptomatic (22%–60%), than asymptomatic cCMV (0%–12.5%). Two studies found that vestibular function deteriorated over time: one in children (mean age 7.2 months) over 10 months and the other (mean age 34.7 months) over 26 months. Conclusions Vestibular dysfunction is found in children with symptomatic and asymptomatic cCMV and in those with and without hearing loss. Audiovestibular assessments should be performed as part of neurodevelopmental follow-up in children with cCMV. Case–controlled longitudinal studies are required to more precisely characterise vestibular dysfunction and help determine the efficacy of early supportive interventions. PROSPERO registration CRD42019131656.

1 September 2025 in Archives of Disease in Childhood
Verified
Journal Article
Closed access
JDJulia R R Dudley
Julia R R Dudley
ASAnnalie Shears
Annalie Shears
GYGeorgina Yan
Georgina Yan
PHPaul T Heath
Paul T Heath
SLShamez N Ladhani
Shamez N Ladhani
KFKaty Fidler
Katy Fidler
Objective: Estimate the incidence of herpes simplex virus (HSV) infections in infants under 90 days in the UK and Ireland and describe clinical presentation and outcomes. Design: Prospective population-based national surveillance study of infants <90 days with HSV infection, using British Paediatric Surveillance Unit (BPSU) methodology (August 2019–February 2022). Results: 117 infants with confirmed HSV infection were identified (6.0 cases/100 000 live births (95% CI 4.9, 7.2)). One-third (34.5%) of infants were premature (24 hours after symptom onset. Infants with disseminated infections presented with non-specific signs of sepsis: 65.8% were afebrile and 73.7% had no SEM lesions. Median C reactive protein at presentation was 4 mg/L (IQR 1–14). Overall mortality was 23.9%, rising to 65.8% among infants with disseminated disease. Of the 41 infants with follow-up data at 24 months, 29.3% had neurodevelopmental impairment (11.8% SEM, 45% CNS, 25% disseminated). Conclusions: Infants with neonatal HSV can present without fever, SEM lesions or elevated infection markers; treatment delay is subsequently common. Outcomes remain poor with high case-fatality rates and long-term morbidity. Clinicians should have a low threshold for empirically testing for and treating herpes in unwell neonates.

30 September 2021
Verified
Conference Paper
Open access
PDF file
KFKaty Fidler
Katy Fidler
PHPaul Heath
Paul Heath
JDJulia Dudley
Julia Dudley
GYGeorgina Yan
Georgina Yan
RLRichard Lynn
Richard Lynn
Background Neonatal herpes simplex virus infection is a rare but dangerous condition with a high mortality and morbidity unless recognised and treated early. A recent study1 suggests that the UK incidence may have increased since the last national surveillance studies were undertaken 15 and 30 years ago.2,3 There is currently no national guidance on when to initiate treatment for suspected neonatal HSV. Rising numbers of HSV cases may support the wider use of empirical treatment. Objectives To define the: (1) current burden of HSV disease and virus types, in UK and Irish infants less than 90 days, over a two-year period, (2) types of HSV disease ie disseminated, meningoencephalitis or skin/eye/mouth disease, (3) presentations and management, (4) source of transmission, (5) antenatal risk factors. Methods Prospective surveillance of HSV infection in infants < 90 days of age in UK and Ireland commenced in July 2019 through the British Paediatric Surveillance Unit (BPSU). Paediatricians reporting cases were requested to complete a detailed semi-anonymised questionnaire. Case notifications & data from completed questionnaires during the first 18 months, July 2019 - Jan 2021, are reported here. Results 137 cases reported to BPSU: 8 were errors, 80 clinicians completed questionnaires, 21 confirmed duplicates, leaving 59 cases for analysis. Estimated incidence is 6.9 cases per 100 000 live births based on 2019 UK & Ireland birth rates. 31 (53%) male, 17 (29%) born <37 weeks. 21 (36%) had disseminated (blood pcr positive), 18 (30%) encephalitis and 20 (34%) skin/eye/mouth (SEM) disease. HSV1: 29 (49%), HSV 2: 25 (42%), unknown:5 (9%). More of those with disseminated and CNS disease had HSV2 infections and more with SEM disease had HSV1. Presenting features of disseminated disease were non specific and only 3/21 (14%) presented with a fever. 10/21 (47.6%) had a CRP of less than 20 at presentation, 11/21 (52.3%) had a transaminitis. Disseminated disease was present in 4/5 (80%) babies born at 37 weeks gestation. Aciclovir was commenced in 54/59 but in only 23/59 (39.0%) on the day of presentation. Overall mortality was 22% but 57% in those with disseminated disease. Mortality by gestation was 60% 37 weeks. Conclusions Incidence of neontatal HSV has doubled since the last national surveillance study. Mortality remains high and presenting features of disseminated disease are non-specific. Absence of fever in 86% of cases demonstrates that HSV should not only be considered in the assessment of the febrile infant. Awareness of this disease needs to be raised to enable early recognition and treatment. References Batra D, Davies P, Manktelow BN, et al. The incidence and presentation of neonatal herpes in a single UK tertiary centre, 2006–2013. Archives of Disease in Childhood 2014;99:916–921. Tookey P, et al. Surveillance of neonatal herpes in the British Isles 2004–2006. Submitted for publication. Tookey P1, Peckham CS. Neonatal herpes simplex virus infection in the British Isles. Paediatr Perinat Epidemiol 1996 Oct;10(4):432–42.

27 November 2023 in Archives of Disease in Childhood - Fetal and Neonatal Edition
Verified
Journal Article
Closed access
PDF file
GYGeorgina Yan
Georgina Yan
ASAnnalie Shears
Annalie Shears
JDJulia R Dudley
Julia R Dudley
PMPaddy McMaster
Paddy McMaster
KFKaty J Fidler
Katy J Fidler

13 April 2026 in Archives of Disease in Childhood
Verified
Journal Article
Closed access
PDF file
ASAnnalie Shears
Annalie Shears
GYGeorgina Yan
Georgina Yan
RHRose Hartzenberg
Rose Hartzenberg
GLGeorge Lawson
George Lawson
SHStephanie Habermann
Stephanie Habermann
KFKaty Fidler
Katy Fidler
The prevalence of invasive bacterial infection in young febrile infants is estimated at 1%–4%, with the highest rates in those <21 days.1 UK guidelines recommend screening all febrile neonates for bacterial infection and starting empiric broad-spectrum antibiotics while awaiting results,2–4 but not routine antiviral therapy. However, a recent UK/Ireland prospective surveillance study reported an increased incidence of neonatal herpes simplex virus (HSV) infection of 6.0 per 100 000 live births, with substantial associated morbidity and mortality.5